The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

NCT01566695 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

216

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: Oral Azacitidine
DRUG: Placebo
OTHER: Best Supportiv Care (BSC)

Sponsor

Celgene